Phase 3 study of Nalbuphine®ER in patients with prurigo nodularis

Trial Profile

Phase 3 study of Nalbuphine®ER in patients with prurigo nodularis

Planning
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Nalbuphine (Primary)
  • Indications Prurigo nodularis
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Nov 2016 New trial record
    • 13 Oct 2016 According to Trevi Therapeutics media release, this study is intended to start in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top